Handelsinvest Investeringsforvaltning reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 34.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,287 shares of the company’s stock after selling 2,746 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Ionis Pharmaceuticals were worth $229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also bought and sold shares of the company. GAMMA Investing LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $26,000. Pingora Partners LLC purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $25,000. Mather Group LLC. purchased a new stake in Ionis Pharmaceuticals in the first quarter worth $29,000. Tennessee Valley Asset Management Partners purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth $34,000. Finally, Sunbelt Securities Inc. bought a new position in shares of Ionis Pharmaceuticals in the first quarter worth $44,000. 93.86% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $41.60, for a total value of $166,649.60. Following the transaction, the executive vice president now owns 19,631 shares in the company, valued at $816,649.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Joseph Klein III sold 6,000 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $42.71, for a total transaction of $256,260.00. Following the transaction, the director now owns 16,346 shares in the company, valued at approximately $698,137.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Baroldi sold 4,006 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the transaction, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The disclosure for this sale can be found here. Corporate insiders own 2.71% of the company’s stock.
Analyst Ratings Changes
View Our Latest Analysis on Ionis Pharmaceuticals
Ionis Pharmaceuticals Trading Up 1.0 %
NASDAQ:IONS opened at $45.60 on Thursday. The company has a debt-to-equity ratio of 4.15, a current ratio of 7.37 and a quick ratio of 7.28. The stock has a fifty day moving average of $40.80 and a 200 day moving average of $44.77. Ionis Pharmaceuticals, Inc. has a 52-week low of $35.95 and a 52-week high of $54.44.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.12. Ionis Pharmaceuticals had a negative return on equity of 107.64% and a negative net margin of 49.49%. The firm had revenue of $119.00 million during the quarter, compared to analyst estimates of $131.42 million. During the same quarter in the previous year, the company posted ($0.87) earnings per share. The company’s revenue was down 9.2% compared to the same quarter last year. On average, equities analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.91 EPS for the current fiscal year.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What is Short Interest? How to Use It
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Insider Trading – What You Need to Know
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.